The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC).
The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC). This is a clinical quality improvement (CQI) initiative to evaluate outcomes within our institution. The data collected will be used to inform new innovative ways to improve EUS-guided liver biopsy with an ultimate goal of improving the quality of patient care. The clinical outcomes of this patient population have not been previously systematically reviewed in MDMC. Currently, the procedure in not being performed routinely at Methodist Dallas Medical Center (MDMC). However, with new technical and physician expertise, this option is now available at our institution. PI will evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients requiring histologic examination of their liver at MDMC.
Study Type
OBSERVATIONAL
Enrollment
24
Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
Methodist Dallas Medical Center
Dallas, Texas, United States
Length of core biopsy
Time frame: 9/1/2017 and 9/1/2019
Number of portal tracts
Time frame: 9/1/2017 and 9/1/2019
Diagnostic yield
We will define an adequate specimen as one containing ≥11 portal tracts or measuring ≥20 mm cumulative core length.
Time frame: 9/1/2017 and 9/1/2019
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.